NRG Therapeutics vs Prime Medicine
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised £50M ($67M) oversubscribed Series B (Sep 2025). First participants dosed in Phase 1 of NRG5051 (Jan 2026). Phase 1 readout expected end of 2026. Oral small molecules targeting mPTP in ALS and Parkinson's.
About
NRG Therapeutics develops first-in-class oral small molecules targeting the mitochondrial permeability transition pore (mPTP) — a protein complex whose aberrant opening triggers the cellular energy failure and neurodegeneration that underlies ALS (amyotrophic lateral sclerosis) and Parkinson's disease. The company raised £50 million ($67 million) in an oversubscribed Series B in September 2025, and dosed the first clinical trial participants for NRG5051 in January 2026, with Phase 1 readout expected by end of 2026.
Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing rapid function restoration after single infusion.
About
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.